Cardiologist, not to mention Wall Street analysts, are the results of several important studies that meet at the American Heart Association this week presented closely monitor.
In particular, are on Monday morning bring researchers developed the results of the rocket AF a study that compared warfarin, Rivaroxaban, blutgerinnung retardant a new drug from Bayer and Johnson and Johnson to prevent strokes in patients with atrial fibrillation.
The question is not only whether the new pill worked as also warfarin, an older drug to take effective but often uncomfortable for patients, but the new drug was how secure when compared to the older drug caused bleeding.
Johnson and Johnson has a Ð food and Drug Administration to approve that for any other purpose - to reduce the risk of large blood clots Rivaroxaban in people the knee or hip replacement surgery are subject to.
But the f.d.a has already approved the first new generation alternative to warfarin. Pradaxa, also known under its chemical name, made by Boehringer Ingelheim, Dabigatran Agency received approval last month as stroke prevention treatment for people with atrial fibrillation.
Meanwhile researchers will present on Wednesday morning, expected that define a study called includes Anacetrapib, cholesterol-Medikament in the development of Merck.It is designed to increase HDL, also known as "good" cholesterol while reducing LDL, also known as "bad" cholesterol.
The meeting continue through Wednesday in Chicago.Can developments in one of my favorite blogs, Larry of cough's CardioBrief or by his Twitter feed @ Cardiobrief follow.
Heart lovers cardiologist, Dr. Harlan Krumholz, the Yale should follow their Twitter feed @ Hmkyale is.
On Monday's Kathleen Sebelius Secretary of health and human services planned the keynote speech at the annual meeting of the National Business Coalition of health liefern.Die non profit group around the country representing more than 7,000 employers, including the implication of the law, discuss employers health overhaul.
About are the f.d.a it a busy week for external experts on Advisory Committee panels, to check the industrial applications for new drugs.
On Tuesday, this is arthritis advisory panel, Benlysta, a human monoclonal antibody of Human Genome Sciences, for the treatment of patients with Lupus prüfen.Am discuss a regulatory path for potential anthrax-Impfstoffe Tuesday the vaccine Advisory Committee and Wednesday, which consider same group approval for Gardasil that Merck to include prevention of anal cancer vaccine of HPV is erweitern.Inzwischen Thursday the Agency plastic surgery Panel, a new handheld device called MelaFind as a system to detect, predict whether moles and skin lesions cancerous device shall be checked.
Towards the end of the week, kidney specialists become aware of developments of the meeting of the American Society of Nephrology in Denver, where late-breaking clinical trials are due will be presented on Saturday.
In particular, presents researcher at Oxford University the results Of the sharp study, one Merck-sponsored study the effectiveness of the use of cholesterol treatments simvastatin and Ezetimibe, also known as the combination tested pill Vytorin on cardiovascular events in patients with chronic kidney disease.
If you want to nominate your favorite blog or Twitter on developments feed in the treatment of kidney disease, please send us a note.
Correction: An earlier version of this post wrong type of specialists who most closely monitor the American Society of Nephrology Conference in Denver running.make are not liver, kidney, specialists.
0 comments:
Post a Comment